Intra-Cellular Therapies (ITCI) Reports Positive Phase 3 Topline Results from Study 501
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Intra-Cellular Therapies (ITCI) PT Raised to $91 at BofA Securities
April 17, 2024 5:13 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $91.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "This morning, ITCI reported positive Ph3 topline results from its first MDD trial (Study 501) assessing Caplyta as an... More
Intra-Cellular Therapies (ITCI) to Resume Trading at 7:30 a.m.
April 16, 2024 7:06 AM EDTIntra-Cellular Therapies (NASDAQ: ITCI) to Resume Trading at 7:30 a.m.
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive DisorderLumateperone 42 mg achieved statistically significant and clinically meaningful results in both the... More